NCT04820608

Brief Summary

Customized remodeled vision (CuRV) is a new corneal cross-linking protocol for keratoconus, combining a transepithelial approach with customized energy application. Our aim is to follow-up our patients and establish the short-and long-term results of CuRV.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2018

Completed
3.1 years until next milestone

First Submitted

Initial submission to the registry

March 25, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 29, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

March 29, 2021

Status Verified

March 1, 2021

Enrollment Period

3.9 years

First QC Date

March 25, 2021

Last Update Submit

March 25, 2021

Conditions

Keywords

keratoconuscross-linkingtransepithelialoxygen-boostedcustomizedCXL

Outcome Measures

Primary Outcomes (2)

  • Spectacle-corrected distance visual acuity

    Measurements will be performed on Early Treatment of Diabetic Retinopathy Study charts in logMAR units

    1-3-6 months, 1 year, 2 years

  • Kmax

    Maximal corneal keratometric value measured on Scheimpflung corneal tomography

    1-3-6 months, 1 year, 2 years

Secondary Outcomes (5)

  • Demarcation line depth

    1 month

  • Thinnest corneal pachymetry

    1-3-6 months, 1 year, 2 years

  • Maximal anterior & posterior elevation

    1-3-6 months, 1 year, 2 years

  • Fourier analysis-calculated maximum decentration

    1-3-6 months, 1 year, 2 years

  • Regularization index

    1-3-6 months, 1 year, 2 years

Study Arms (1)

Customized, transepithelial cross-linking

EXPERIMENTAL

All study patients will be treated according to the customized remodeled vision protocol

Device: Cross-linking

Interventions

Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.

Also known as: Customized remodeled vision
Customized, transepithelial cross-linking

Eligibility Criteria

Age12 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Topographic evidence of keratoconus:
  • maximum corneal curvature (Kmax) ≥47.00 D,
  • localized steepening on topographic maps,
  • localized elevation in the anterior and posterior corneal surfaces.

You may not qualify if:

  • Hypersensitivity to riboflavin
  • Thinnest corneal pachymetry \< 380 μm
  • History of corneal surgery, including previous cross-linking
  • Corneal scarring
  • Aphakia
  • Pseudophakia
  • Any visually significant ocular condition

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ophthalmica Eye Institute

Thessaloniki, Kalamaria, 54655, Greece

Location

Related Publications (1)

  • Seiler TG, Fischinger I, Koller T, Zapp D, Frueh BE, Seiler T. Customized Corneal Cross-linking: One-Year Results. Am J Ophthalmol. 2016 Jun;166:14-21. doi: 10.1016/j.ajo.2016.02.029. Epub 2016 Mar 2.

    PMID: 26944278BACKGROUND

MeSH Terms

Conditions

Keratoconus

Condition Hierarchy (Ancestors)

Corneal DiseasesEye Diseases

Study Officials

  • Miltos Balidis, PhD

    Ophthalmica Eye Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2021

First Posted

March 29, 2021

Study Start

February 1, 2018

Primary Completion

January 1, 2022

Study Completion

January 1, 2022

Last Updated

March 29, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations